Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CG Oncology, Inc.CGON · Entity 3735 | President and COO | April 15, 2026 | April 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CG Oncology, Inc.
Report date April 15, 2026 · Filed April 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $67.68 · Expires 2036-04-14 | Direct | 107,508 |
Reported balance
After 2026-04-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-15 · Grant · Acquired 107,508 · Balance 107,508 F1: 1/48th of the shares subject to the option vest monthly following April 15, 2026, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares subject to the option vest monthly following April 15, 2026, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 15, 2026 Filed Apr 16, 2026 20:15 UTC | CG Oncology, Inc. CGON · Entity 3735 | GrantEmployee Stock Option (Right to Buy) · Derivative | 107,508 | $0.00 Strike: $67.68 | $0.00 |
DisclosureSEC source: 0001193125-26-159031 · ownership.xml · derivative · entry 1 Bellete Ambaw · CIK 0002007090 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,508 Underlying: Common Stock · 107,508 shares Expires 2036-04-14 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following April 15, 2026, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| April 15, 2025 Filed Apr 16, 2025 20:15 UTC | CG Oncology, Inc. CGON · Entity 3735 | GrantEmployee Stock Option (Right to Buy) · Derivative | 284,816 | $0.00 Strike: $20.11 | $0.00 |
DisclosureSEC source: 0000950170-25-054740 · ownership.xml · derivative · entry 1 Bellete Ambaw · CIK 0002007090 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 284,816 Underlying: Common Stock · 284,816 shares Expires 2035-04-14 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following April 15, 2025, the vesting commencement date, subject to the Report Person's continuous service to the Issuer through each vesting date. Read SEC document |
| October 04, 2024 Filed Oct 7, 2024 21:00 UTC | CG Oncology, Inc. CGON · Entity 3735 | GrantStock Option (Right to Buy) · Derivative | 175,500 | $0.00 Strike: $36.63 | $0.00 |
DisclosureSEC source: 0000950170-24-113297 · ownership.xml · derivative · entry 1 Bellete Ambaw · CIK 0002007090 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,500 Underlying: Common Stock · 175,500 shares Expires 2034-10-03 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following October 4, 2024, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.